TABLE 2

Concerns About Treatment of NHL Patients with ⁹⁰Y-Ibritumomab Tiuxetan or ¹³¹I-Tositumomab Grouped by Treatment or No Treatment

	Mean rating
Concern	Does treat	Does not treat	P
We have concerns about the radiation safety	1.86	1.87	0.77
⁹⁰Y-ibritumomab tiuxetan administration is too complicated in general	1.88	1.72	0.83
We have concerns about the dosimetry procedure	2.01	2.00	0.45
There might be unexpected late side effects of ¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment (myelodysplastic syndrome)	2.28	2.38	0.47
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan takes too much time from my practice in general	2.29	2.01	0.22
Most nuclear physicians are not trained to administer potential myeloablative therapies such as ⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab^*	2.39	2.51	0.06
⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab therapy provides poor payment for the time and effort in the radiolabeling process	2.49	2.51	0.33
Concerns exist that subsequent treatments will not be possible after ¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan administration	2.53	2.46	0.22
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment does not have enough reported randomized studies^*	2.58	2.46	<0.01
¹³¹I-tositumomab administration is too complicated in general	2.62	2.41	0.27
⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab therapy provides poor payment for the time and effort in the administration process	3.01	2.88	0.62
Oncologists and hematologists prefer to treat by themselves with nonradioactive compounds	3.47	3.43	0.34
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment is too expensive^*	3.60	3.34	<0.01